Biomarker-Defined Subsets of Common Diseases: Policy and Economic Implications of Orphan Drug Act Coverage
View/ Open
Published Version
https://doi.org/10.1371/journal.pmed.1002190Metadata
Show full item recordCitation
Kesselheim, Aaron S., Carolyn L. Treasure, and Steven Joffe. 2017. “Biomarker-Defined Subsets of Common Diseases: Policy and Economic Implications of Orphan Drug Act Coverage.” PLoS Medicine 14 (1): e1002190. doi:10.1371/journal.pmed.1002190. http://dx.doi.org/10.1371/journal.pmed.1002190.Abstract
Aaron Kesselheim and colleagues examine orphan-designated drugs approved between 2009 and 2015 in the United States.Other Sources
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5207392/pdf/Terms of Use
This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAACitable link to this page
http://nrs.harvard.edu/urn-3:HUL.InstRepos:30371184
Collections
- HMS Scholarly Articles [17922]
- SPH Scholarly Articles [6362]
Contact administrator regarding this item (to report mistakes or request changes)